Shakher Ramdave

Monash Health — Australia

Medicine · Health Sciences

18h-index3.2kcitations29works61.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(14), Radiopharmaceutical Chemistry and Applications(9), Prostate Cancer Diagnosis and Treatment(8), Medical Imaging Techniques and Applications(4), Radiomics and Machine Learning in Medical Imaging(4)

Publications28 total

Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
Nature Medicine·2025· 18 cited
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
The Lancet Oncology·2025· 39 cited
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
The Lancet Oncology·2024· 126 cited
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
The Lancet Oncology·2023· 172 cited
Can <scp> <sup>68</sup> Ga‐PSMA positron emission tomography </scp> and multiparametric <scp>MRI</scp> guide treatment for biochemical recurrence after radical prostatectomy?
British Journal of Urology·2023· 5 citedOpen Access
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
The Lancet Oncology·2022· 240 cited
Neurolymphomatosis: an uncommon manifestation of lymphoma – detection and therapeutic monitoring through 18F-fluorodeoxyglucose positron-emission tomography and computed tomography imaging
BMJ Case Reports·2022· 5 citedOpen Access
<sup>68</sup> Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography Maximum Standardized Uptake Value as a Predictor of Gleason Pattern 4 and Pathological Upgrading in Intermediate-Risk Prostate Cancer
The Journal of Urology·2021· 19 cited
<sup>68</sup>Ga‐prostate‐specific membrane antigen (PSMA) PET/CT as a clinical decision‐making tool in biochemically recurrent prostate cancer
Asia-Pacific Journal of Clinical Oncology·2021· 3 citedOpen Access
177Lu-PSMA-617 versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer: a randomised, open-label, phase 2 trial (TheraP)
2021
Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology
European Urology Oncology·2021· 28 cited
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
The Lancet·2021· 1.0k cited
No needle to fear: An approach to needle phobic patients.
PubMed·2020Open Access
ProPSMA Study: A prospective randomised multi-centre study of PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy
Asia-Pacific Journal of Clinical Oncology·2020
Detection and localisation of primary prostate cancer using <sup>68</sup> gallium prostate‐specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology
British Journal of Urology·2019· 98 citedOpen Access
Ga-68-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer after definitive treatment: An Australian prospective study
Asia-Pacific Journal of Clinical Oncology·2019
P3.03-025 Investigating Phenotypic and Genomic Heterogeneity in Malignant Pleural Mesothelioma
Journal of Thoracic Oncology·2017Open Access
Utility of SUVmax on 18 F-FDG PET in detecting cervical nodal metastases
Cancer Imaging·2016· 30 citedOpen Access
Neuraxial Anesthesia Reduces Lymphatic Flow: Proof-of-Concept in First In-Human Study
Anesthesia & Analgesia·2016· 14 cited
Dynamic four-dimensional computed tomography for preoperative assessment of lung cancer invasion into adjacent structures†
European Journal of Cardio-Thoracic Surgery·2014· 23 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Michael S. Hofman(11), Ian D. Davis(11), Roslyn J. Francis(10), Louise Emmett(9), Shahneen Sandhu(9), Anthony M. Joshua(9), Ian Kirkwood(9), Natalie Rutherford(9), Sze-Ting Lee(9), Arun Azad(9), Martin R. Stockler(9), Andrew Martin(9), Amir Iravani(8), David A. Pattison(8), Thean Hsiang Tan(8), Siobhan Ng(8), Craig Gedye(8), Andrew Weickhardt(8), Andrew M. Scott(8), Andrew Redfern(8)